Aditya Kohli

Aditya Kohli, Ph.D., is a Partner at Frazier Life Sciences, where he leads company creation and investment strategy for innovative biopharmaceutical ventures. Based in New York, Dr. Kohli plays a pivotal role in identifying, backing, and building therapeutics-focused biotech companies—particularly those developing novel treatments for significant unmet medical needs. His work spans both early-stage private and small- to mid-cap public companies within the global biopharmaceutical sector, with a focus on therapeutics and drug development.

Before becoming Partner in 2025, Dr. Kohli was a Venture Partner at Frazier Life Sciences and previously served in operating roles including Chief Business Officer at Phathom Pharmaceuticals (NASDAQ: PHAT), Chief Operating Officer at HilleVax (NASDAQ: HLVX), and Board Director/co-founder at Scout Bio, which was acquired by Ceva Santé Animale. He currently serves on the board of HilleVax and has co-founded and built multiple Frazier-backed biotech companies resulting in successful IPOs and acquisitions.

Dr. Kohli holds a Ph.D. in Bioengineering from the joint program at University of California, Berkeley and UCSF, as well as B.S. and M.Eng. degrees in Bioengineering from MIT. He began his career as an Engagement Manager at McKinsey & Company, advising global life sciences firms on business development and R&D strategy. Dr. Kohli is recognized for his expertise in therapeutic company creation, biotech operating leadership, and strategic investments across the pharmaceutical innovation landscape.